Wall Street Zen lowered shares of Immunic (NASDAQ:IMUX – Free Report) from a sell rating to a strong sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.
Several other equities analysts also recently commented on the company. Cantor Fitzgerald initiated coverage on Immunic in a research report on Friday, October 23rd. They issued an “overweight” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, August 26th. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Immunic in a research report on Thursday, September 10th. Wedbush reissued an “outperform” rating and set a $45.00 target price on shares of Immunic in a research note on Thursday, September 10th. Finally, Zacks Research cut shares of Immunic from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 10th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.43.
Check Out Our Latest Stock Report on IMUX
Immunic Price Performance
Shares of IMUX traded down $0.27 during mid-day trading on Friday, reaching $7.52. 105,145 shares of the company’s stock traded hands, compared to its average volume of 283,926. The stock’s 50-day moving average is $8.70 and its two-hundred day moving average is $11.52. Immunic has a 12 month low of $5.06 and a 12 month high of $17.43. The stock has a market cap of $102.57 million, a P/E ratio of -1.72 and a beta of 1.48.
Immunic (NASDAQ:IMUX – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Research analysts predict that Immunic will post -3.69 earnings per share for the current year.
Institutional Trading of Immunic
A number of large investors have recently modified their holdings of the company. Marshall Wace LLP boosted its holdings in shares of Immunic by 242.8% in the third quarter. Marshall Wace LLP now owns 359,319 shares of the company’s stock valued at $3,342,000 after purchasing an additional 254,503 shares during the period. State Street Corp increased its holdings in Immunic by 36.9% during the 3rd quarter. State Street Corp now owns 83,859 shares of the company’s stock worth $780,000 after purchasing an additional 22,600 shares during the period. Aberdeen Group plc increased its holdings in Immunic by 32.3% during the 3rd quarter. Aberdeen Group plc now owns 1,090,427 shares of the company’s stock worth $10,141,000 after purchasing an additional 266,034 shares during the period. Alps Advisors Inc. raised its position in Immunic by 28.0% during the 3rd quarter. Alps Advisors Inc. now owns 17,694 shares of the company’s stock valued at $165,000 after purchasing an additional 3,870 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Immunic by 21.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company’s stock valued at $69,000 after purchasing an additional 1,400 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.
Top Immunic Stories
Here are a few of the latest stories about IMUX:
- Positive Sentiment: The company said its pivotal ENSURE-1 and ENSURE-2 trials remain on track to report top-line results in December. It also expects its funding to last into late 2027, giving it runway beyond the upcoming readout. Article: Immunic on track for December Phase 3 readout in relapsing MS, funded into late 2027
- Neutral Sentiment: Immunic is preparing to start its Phase 3 PROTECT-MS trial for progressive MS, with first-patient enrollment expected in the first half of 2027. The company also announced leadership appointments intended to support regulatory and commercial readiness. Article: Immunic reports third-quarter 2026 financial results and provides corporate update
- Negative Sentiment: Third-quarter results showed a $42.3 million net loss, with a loss of $0.99 per share—worse than the $0.79 loss analysts expected. Coverage cited higher expenses and the earnings miss as reasons for investor concern. Article: Immunic Q3 loss widens on higher expenses
Immunic Company Profile
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.
Further Reading
- Five stocks we like better than Immunic
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
